Outlook Therapeutics is trading at $0.50, up 6.13%, amid a biotech-sector rally; available information points to sector sentiment rather than a confirmed company-specific catalyst. - XBI is reported up 2.20%, alongside positive clinical news from Krystal Biotech. - No clear company-specific announcement dated October 15 was identified. The latest surfaced company release was the October 9 commercial-chief appointment, not a new catalyst for this move. - No trading-volume details were provided.